多汗症治療市場 - 按類型、治療、年齡、最終用戶、全球預測

Hyperhidrosis Treatment Market - By Type, Treatment, Age, End-user, Global Forecast 2024-2032

出版日期: 2024年06月13日 | 出版商:

Global Market Insights Inc. | 英文 189 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在治療選擇的快速進步以及皮膚科和美容診所的擴張的帶動下，多汗症治療市場規模預計從 2024 年到 2032 年將以 5.3% 的複合年成長率擴大。

最近，創新正在幫助開發更有效、更有針對性的療法，例如新藥物和微創手術，以覆蓋更廣泛的患者群體。此外，皮膚科和美容診所也正在提高其能力和服務，為多汗症提供專門的治療，以加強患者的取得和照護。例如，2024年6月，Botanix Pharmaceuticals宣布美國FDA已批准其12.45%的Sofdra（索匹羅銨）凝膠用於治療腋下出汗過多，這標誌著多汗症治療方案的重大進步。

整個市場分為類型、治療、年齡、最終用戶和地區。

根據治療情況，預計從2024 年到2032 年，肉毒毒素注射領域的多汗症治療市場價值將大幅成長，因為人們擴大採用肉毒毒素注射來更好地控制自己的症狀並提高生活品質。這種方法包括將少量肉毒桿菌注射到受過度出汗影響的區域，例如腋下、手掌或腳部。此外，醫療保健提供者正在擴大這些注射劑的使用，為患者提供更個人化和針對性的治療。

由於對多汗症提供專門治療的需求不斷成長，預計到 2032 年，皮膚科診所最終用戶領域的多汗症治療行業將以複合年成長率大幅擴張。這些診所正在採用先進的療法，例如肉毒桿菌注射和新的局部療法，以有效解決出汗過多的問題。皮膚科醫生也致力於完善治療方案並提供個人化護理計劃，以更好地管理多汗症症狀。

從地區來看，由於可支配收入的增加以及化妝品和美容行業的發展，歐洲多汗症治療市場規模預計將在 2024 年至 2032 年間擴大。該地區的美容和美容行業正在整合新療法和技術，以更有效地解決多汗症問題。此外，我們不斷加強努力，增強治療選擇並擴大可用性。為歐洲各地尋求緩解出汗過多的個人提供更好的解決方案並提高整體治療效果的持續改進將有利於行業的成長。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

AbbVie Inc.
Avanor Healthcare Ltd.
Brickell Biotech Inc.
Dermadry Laboratories Inc.
Dermavant Sciences Inc.
Hugel, Inc.
Eirion Therapeutics, Inc
Eli Lilly and Company
Intas Pharmaceuticals Ltd
Kaken Pharmaceutical Co., Ltd.
Maruho Co., Ltd.
miraDry, Inc.
SweatBlock

簡介目錄

Product Code: 9862

Hyperhidrosis Treatment Market size is projected to expand at 5.3% CAGR from 2024 to 2032, led by rapid advancements in treatment options along with the expansion of dermatology and aesthetic clinics.

Of late, innovations are helping in developing more effective and targeted therapies, such as new medications and minimally invasive procedures to reach a broader patient base. Moreover, dermatology and aesthetic clinics are also increasing their capacity and services to offer specialized treatments for hyperhidrosis for enhancing patient access and care. For instance, in June 2024, Botanix Pharmaceuticals announced that the U.S. FDA had approved its Sofdra (sofpironium) gel, 12.45%, for treating excessive underarm sweating, marking a significant advancement in hyperhidrosis treatment options.

The overall market is segregated into type, treatment, age, end-user, and region.

Based on treatment, the hyperhidrosis treatment market value from the botulinum toxin injections segment is estimated to rise at significant rate from 2024 to 2032 due to rising adoption for offering individuals more control over their symptoms and enhancing quality of life. This approach involves injecting small amounts of botulinum toxin into areas affected by excessive sweating, such as the underarms, palms, or feet. Moreover, healthcare providers are expanding the use of these injections to offer more personalized and targeted treatments for patients.

Hyperhidrosis treatment industry from the dermatology clinics end-user segment is anticipated to expand at substantial CAGR up to 2032, owing to the growing requirement to offer specialized treatments for hyperhidrosis. These clinics are incorporating advanced therapies, such as botulinum toxin injections and new topical treatments to address excessive sweating effectively. Dermatologists are also working on refining treatment protocols and providing personalized care plans to better manage hyperhidrosis symptoms.

Regionally, the Europe hyperhidrosis treatment market size is projected to expand between 2024 and 2032, on account of the rising disposable incomes and the growing cosmetic and aesthetic sector. The cosmetic and aesthetic sectors in the region are integrating new therapies and technologies to address hyperhidrosis more effectively. Additionally, increasing efforts are enhancing treatment options and expanding availability. The ongoing enhancements for offering better solutions and increasing the overall treatment efficacy for individuals seeking relief from excessive sweating across Europe will favor the industry growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of hyperhidrosis
  - 3.2.1.2 Growing awareness and diagnosis rates
  - 3.2.1.3 Advancements in treatment technologies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side effects and risk associated with treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Axillary hyperhidrosis
5.3 Palmar hyperhidrosis
5.4 Plantar hyperhidrosis
5.5 Other types

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Topical treatment
6.3 Oral medication
- 6.3.1 Anticholinergics
- 6.3.2 Other oral medications
6.4 Botulinum toxin injections
6.5 Iontophoresis
6.6 Surgical treatment

Chapter 7 Market Estimates and Forecast, By Age, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Below 50 years
7.3 Above 50 years

Chapter 8 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Ambulatory surgical centers
8.4 Dermatology clinics
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa